Benfotiamine has been confirmed not only to directly inhibit NADPH oxidase activity but also to prevent the pathway of protein kinase C (PKC), thus blocking the activation of NF-κB in patients with diabetes [13]. Here, NFKB1 is linked to diabetes mellitus.